Among the TRP superfamily, the transient receptor potential melastatin-like subfamily member 4 (TRPM4) has recently emerged as an important drug target for stroke therapy [10,11,12,13,14,15,16,17] and many other diseases [18,19,20]. This evidence concerns the gene TRPM4 and stroke disorder.